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In a prior  report we  presented  evidence that insulin- 
like growth factor-I (IGF-I) can act in an autocrine 
fashion by demonstrating that FRTL-5 cells trans- 
fected  with hIGF-IA fusion  genes express  and  secrete 
biologically active  IGF-I that  renders  the  stimulation 
of DNA synthesis  in  FRTL-5  cells  independent of heir 
requirement  for exogenous  IGFs or insulin.  To deter- 
mine if  IGF-1’s autocrine  actions  require  secretion or 
can be mediated by interactions with intracellular 
receptors,  we  have  created a new line of FRTL-5 cells 
that express a mutant IGF-IA precursor  containing  the 
endoplasmic  reticulum  retention  amino  acid  sequence, 
Lys-Asp-Glu-Leu (KDEL), at its carboxyl terminus. 
The mutant IGF-IA/KDEL precursor  expressed  by  sta- 
bly  transfected  FRTL-5  cells  was  shown  to  be  retained 
intracellularly  and  to  have biological activity compa- 
rable  with  mature IGF-I, as judged by  the  activity of 
partially  purified IGF-IA/KDEL in wild type  FRTL-5 
cells. Expression of IGF-IA/KDEL in FRTL-5 cells, 
however,  neither  augmented  TSH-stimulated DNA 
synthesis  nor timulated  IGF-binding  protein-5 
expression, as does IGF-IA expression  in  transfected 
FRTL-5 cells and  the  addition of exogenous  IGF-I to 
wild type FRTL-5 cells. IGF-IA/KDEL expression, 
however,  desensitized FRTL-5 cells to  the  actions of 
exogenous  IGF-I  despite having only  minimal  effects 
on cell surface  type I receptor  number,  suggesting that 
intracellular IGF-I is capable of significant biological 
actions. The  failure of IGF-IA/KDEL to  replicate  the 
actions of secreted  IGF-I,  taken  together  with  the  find- 
ings  that a monoclonal antibody  against  IGF-I  blocked 
IGF-1’s actions  in  IGF-I-secreting  transfected  FRTL-5 
cells,  provides  evidence  that  IGF-I  secretion  and  inter- 
action with cell surface type I IGF receptors is the 
dominant mechanism of IGF-1’s autocrine actions. 
The  insulin-like growth factors  (IGFs),’ like other growth 
factors,  are  thought  to  exert  many of their growth and differ- 
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entiation  promoting  actions  through  autocrine  pathways (1- 
3). The  findings  that  both  IGFs  and  IGF receptors often  are 
expressed in cells known to respond to  IGFs  and  that mono- 
clonal antibodies directed against IGFs often abolish IGF- 
dependent effects in  the  absence of exogenous IGFs provide 
cogent arguments for invoking  autocrine modalities of action 
(4-6). The precise mechanisms of IGF-stimulated  autocrine 
actions, however, remain largely unknown. Among the ques- 
tions  relevant  to  the  autocrine  mechanisms of IGF  actions is 
the cellular  location of the  interaction between the  IGFs  and 
IGF receptors. Concurrent synthesis of both IGF and its 
receptor molecules raises  the possibility that  autocrine  actions 
may be stimulated  intracellularly  prior  to  IGF secretion. As a 
first step toward answering such questions, we created an 
autocrine model of IGF-I  action  in  FRTL-5 cells by generating 
cell lines  that  express a hIGF-IA fusion gene driven either by 
the mouse metallothionein-I (MT-I) or IGF-I1 5’ (5’11) ge- 
nomic  regulatory  regions (7). FRTL-5 cells are a diploid, non- 
transformed line of rat thyroid follicular cells (8) whose 
growth in  culture is dependent  upon  the presence of TSH  and 
IGFs  or  insulin (9-11). Compared to wild type  FRTL-5 cells, 
these  IGF-I-expressing  FRTL-5 cells exhibit high basal DNA 
synthesis and their mitogenic response to  TSH is indistin- 
guishable from  the response of wild type cells to  TSH when 
IGF-I is added exogenously ( 7 ) .  
We now extend  these  investigations  to  ask  whether secre- 
tion of IGF-I  is necessary for its  autocrine  actions.  Taking 
advantage of known  capacity of specific amino acid  sequences 
to  cause  retention of proteins  in  the endoplasmic  reticulum 
(12, 13), we have created a new line of FRTL-5 cells that 
express a mutant  IGF-IA  precursor  containing  the  amino acid 
sequence, Lys-Asp-Glu-Leu (KDEL),  at  its carboxyl termi- 
nus. As predicted, the  mutant  IGF-IA/KDEL  precursor ex- 
pressed by stably  transfected  FRTL-5 cells is retained  intra- 
cellularly. While this IGF-IA/KDEL mutant was shown to 
possess biologic activity comparable to mature IGF-I, its 
expression in  FRTL-5 cells  does not replicate the  autocrine 
actions previously demonstrated for IGF-I  in  transfected 
FRTL-5 cells bearing  IGF-IA  transgenes.  This  observation, 
taken  together  with  the findings that a  monoclonal antibody 
against  IGF-I blocks IGF-1’s actions  in  IGF-I-secreting  trans- 
fected FRTL-5 cell lines,  provides strong evidence that  IGF- 
I secretion  and  interaction with cell surface  receptors is nec- 
essary for its  autocrine  actions. 
EXPERIMENTAL  PROCEDURES 
Materials-Coon’s modified Ham’s F-12 medium (Coon’s F-12), 
newborn calf serum, cysteine-free Eagle’s minimum  essential medium 
were purchased from GIBCO. Bovine insulin, human transferrin, 
mouse y globulin (mIgG),  protein A-Sepharose, and G418 were pur- 
chased  from Sigma.  Bovine TSH (1.23 units/mg) for cell culture was 
purchased  from Armour (Kankakee,  IL), while purified  bovine TSH 
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(30 units/mg) for thymidine  incorporation  studies was a gift from the 
National Hormone and Pituitary Program (National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, 
MD). Recombinant  human IGF-I  (rhIGF-I) was obtained from Ge- 
nentech  (South  San Francisco, CA). [methyl-3H]Thymidine (6.5 mCi/ 
mmol) and [ ~ u - ~ * P ] ~ C T P  (3,000 mCi/mmol) were obtained from 
Amersham Corp. ~-[~'S]cysteine (1139.9 Ci/mmol) was purchased 
from Du Pont-New England Nuclear. FRTL-5 cells (ATCC CRL 
8305) were kindly provided by Dr. Leonard Kohn (Section of Cell 
Regulation, NIDDK). Taq polymerase was purchased from Cetus 
(Norwalk, CT). 
Construction of an IGF-Z Transgene Containing a KDEL Se- 
quence-A polymerase chain reaction (PCR)-directed mutagenesis 
strategy was used to make a mutant human IGF-IA fusion gene 
containing  the endoplasmic reticulum retention sequence KDEL (see 
Fig. 1 and  its legend for details of the methods  used). The hIGF-IA 
expression vector pMIG (14,15) was used as a  template for mutagen- 
esis.  PCR amplification was performed with Taq polymerase accord- 
ing  to  the specifications of the manufacturer (Perkin-Elmer  Cetus) 
using  a Perkin Elmer DNA thermal cycler. The  resultant plasmid, 
called  pNEO/IA/KDEL, was subjected to DNA sequencing  (16) to 
confirm  the appropriate  insertion of the  KDEL encoding sequence 
and  to exclude unintended alterations in the coding sequence. 
Transfection and Culture of FRTL-5 Cells-Transfection of FRTL- 
5 cells with pNEO/IA/KDEL was performed with the calcium phos- 
phate precipitation  method, as described previously (7, 17). As with 
the  other stably  transfected FRTL-5 cells used in  this study (7), cells 
were selected with the neomycin analog, G418, and single colonies 
isolated with cloning rings prior to amplification. After 4-5 passages, 
cells that had genomically integrated the KDEL mutant IGF-IA 
transgene were aliquoted and frozen as glycerol stocks in liquid N1. 
Similar procedures were used in preparing and preserving the  other 
transfected FRTL-5 lines used in this study (7). These include: 
pNEOMIG transfected FRTL-5 cells, which express  a fusion of the 
rat somatostatin signal peptide and IGF-IA, driven by the MT-I 
promoter;  p5'II/IA-transfected cells, which express the same trans- 
gene driven by mIGF-I1 5' genomic flanking region; and  p5'II/NEO- 
transfected cells, which express the neomycin resistance gene under 
the regulation of the mIGF-115' genomic flanking region, thus serving 
as control-transfected cells that do not express  IGF-I. 
Unless specified otherwise, all wild type and transfected FRTL-5 
cells used in this study were  of similar passage number (passage 25- 
30) and were  grown  up in 100-mm dishes in Coon's F-12 containing 
5% calf serum and three hormones (3H): TSH (1 milliunit/ml), 
insulin (10 pglml),  and  transferrin  (5 pg/ml). 
Radioimmunoassay (RIA)-To obtain conditioned media and cell 
lysates for IGF-I RIA, quiescent cells were incubated in Coon's F-12 
with 0.1% BSA for 24 h. After collecting the medium, cells were 
harvested in 80 mM sodium citrate, washed twice with phosphate- 
buffered saline (PBS),  and  then lysed in a buffer consisting of 150 
mM NaCl, 1% Nonidet  P-40, and 50 mM Tris,  pH 8.0 (lysis buffer). 
All cell lysates and conditioned media were incubated with equal 
volumes of 0.4 M acetic acid for 45 min and  then neutralized  prior to 
RIA (18, 19). 
Characterization of "S-Labeled Transgene IGF-I-In vitro labeling 
of synthesized  proteins with [35S]cysteine, immunoprecipitation  with 
a rabbit  antiserum to  hIGF-I (UBK 487; kindly donated by Dr. Louis 
E. Underwood), and SDS-PAGE analysis of transgene IGF-I were 
performed, as described previously (7). 
Partial Purification of IGF-Z from Cell Lysates-Cells were collected 
from  3  near-confluent  T-150 flasks, washed twice with PBS, resus- 
pended in 300 pl of 1 M acetic acid, and lysed by repeated freezing 
and thawing. Lysates then were centrifuged for 15 min, and the 
supernatant collected and neutralized. An IGF-I polyclonal antibody 
immobilized on glass beads was then added to  the  supernatant,  and 
the mixture was shaken gently for 1 h  on ice, washed with PBS  and 
then with distilled (d) HIO. Antibody-associated IGF-I was eluted 
with 1 M acetic acid and  the eluate lyophilized. These lysate IGF-I 
preparations were resuspended in 50 pl dH,O and stored at  -80 "C 
until  their bioactivity was evaluated by assessing the capacity of  30 
p1 of each preparation to  stimulate thymidine  incorporation into wild 
type  FRTL-5 cells. 
[methyl-'3H]Thymidine Incorporation Assays-Incorporation of 
[meth~l-~Hlthymidine  into  FRTL-5 cells was performed as described 
previously (7, 11). 
Ligand Blot Analysis of ZGF-binding Proteins-Ligand blotting was 
performed as previously described (20). Conditioned media were 
collected from single 100-mm dishes of near-confluent cells incubated 
with Coon's F-12 for 24 h. After removing cellular debris by centri- 
fuging at  3000 rpm for 15 min, media were dialyzed against 200 
volumes of 0.1% acetic acid at  4 "C using Spectropor-3 membrane 
(molecular weight cut-off 3,000) and concentrated 100-fold by using 
polyethylene glycol (Mr = 8000). Concentrated media were electro- 
phoresed  through 12.5% discontinuous SDS-polyacrylamide gel elec- 
trophoresis (PAGE) and transferred to nitrocellulose filters (0.45 
pm),  and  the  resultant blot was incubated  with  a  mixture of '*'I-IGF- 
I and '2'I-IGF-II. After several successive washes, blots were exposed 
to Kodak X-AR x-ray film at  -70 "C to determine the relative 
migration of proteins capable of binding radiolabeled IGFs. The 
relative intensity of autoradiographic signals was determined by 
densitometric  scanning. 
RNA Analysis-Total RNA was isolated from cells grown to con- 
fluence in single 100-mm dishes, and  Northern hybridization  analyses 
were performed as described previously (7,21, 22), using  a  32P-labeled 
644-bp rat IGF-binding protein-5  (IGFBP-5; bp 558-1201; Ref. 23) 
cDNA probe  generated from rat liver reverse transcribed total RNA 
by PCR. Autoradiographic bands were quantified by scanning  densi- 
tometry,  as with ligand blots. 
Affinity Cross-linking-The cells were grown to confluence in 35- 
mm dishes in 3H Coon's F-12 culture medium with 5% calf serum 
and, after two PBS washes, were reincubated for another 24 h in 
Coon's F-12 with 0.1% BSA. After washing  with HEPES buffer three 
times, cells were incubated with '2sI-IGF-I (6 X 10' cpm/dish) in 
HEPES binding buffer with 0.5% BSA with or without 200 ng/ml 
unlabeled IGF-I or 100 pg/ml insulin for 18 h at  4 "C. The cells were 
then washed with HEPES buffer three times, and 0.1 mM disuccin- 
imidyl suberate in HEPES buffer was added for 15 min at  room 
temperature (24). The reaction was terminated by the addition of 9 
ml of 10 mM Tris-HC1, pH 7.4, with 1 mM EDTA for 15 min. '"I- 
IGF-I  cross-linked cells were solubilized in 2%  SDS, 0.05 M Tris-HC1, 
and 0.1 M DTT,  and subjected to  SDS-PAGE analysis and  autoradi- 
ography. 
IGF-Z Binding Assay-Specific '"I-IGF-I binding to cell surface 
sites was measured on monolayers of wild type and transfected FRTL- 
5 cells as previously described (25), with  minor modifications. Cells 
were grown to confluence in 24-well plates. After removing culture 
media (3H Coon's F-12 with 5% calf serum) and washing with PBS 
twice, cells were incubated with Coon's F-12,0.1% BSA for 24 h, then 
washed three times with cold HEPES binding buffer containing 20 
mM HEPES,  pH 7.4, 120 mM NaC1, 5 mM KC1, 1.2 mM MgSO,, 10 
mM NaHC03, 1.3 mM CaC12, 1.2 mM KH2P04, with 0.5% BSA and 
incubated  with '251-IGF-I (26,000 cpm/ml, specific activity = 267 pCi/ 
pg IGF-I) plus  various concentrations of unlabeled IGF-I in a  final 
volume of 0.5 ml at 4 "C for 18 h. After removing the binding buffer, 
the monolayers were washed four times with cold PBS containing 
0.5% BSA, then solubilized in 0.5  ml of 0.1% SDS, 0.2 M NaOH, and 
radioactivity  determined in a Packard Auto-Gamma 5650. 
RESULTS 
The Expression of thepNEO/IA/KDEL Construct in FRTL- 
5 Cells Results in  Intracellular Accumulation of the IGF-IA/ 
KDEL Precursor-In a previous report we described the cre- 
ation of autocrine models of IGF-I  action  in FRTL-5 cells (7). 
Two plasmids encoding a  hIGF-I fusion gene, driven either 
by mouse MT-I or IGF-I1 5' genomic regulatory regions 
(designated pNEOMIG and p5'II/IA, respectively), were 
transfected. With  either plasmid, stable lines of transfected 
FRTL-5 cells secreted IGF-I  into 24-h conditioned medium 
in concentrations ranging between 0.5 and 3 ng/ml. These 
lines exhibited high basal DNA synthesis and had a DNA 
synthetic response to  TSH  that was indistinguishable from 
that induced by TSH and IGF-I in wild type or control- 
transfected cells (p5'II/NEO). In  the present study a mutant 
hIGF-IA expression vector containing a sequence encoding 
the KDEL endoplasmic reticulum retention signal, designated 
pNEO/IA/KDEL, was constructed and transfected into 
FRTL-5 cells (Fig. 1). After transfection and selection, single 
G418-resistant colonies were screened for IGF-I expression 
by  RIA. As anticipated, immunoreactive IGF-I was detectable 
in cell lysates of transfectants,  but not  in their conditioned 
media. In  the two colonies chosen for detailed characteriza- 
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FIG. 1. Construction of the hIGF-IA/KDEL expression vec- 
tor, pNEO/IA/KDEL. Panel A, schematic of the  strategy  to  create 
pNEO/IA/KDEL. Initially,  two  DNA fragments were amplified from 
the hIGF-IA expression vector, pMIG (14, 15),  one of 482 bp using 
primers A and I3 and one of 474 bp using primers C and D. Each 
amplification used a primer containing a 5' tail complementary to 
the 5'  tail of a  primer used to amplify the  other  fragment ( B  and C). 
The 5'  tails of these  primers ( B  and C) contained  the  KDEL encoding 
sequence (C) or its complement ( B ) ,  as well as  additional comple- 
mentary sequence. Consequently, the single-stranded  DNA resulting 
after melting  each PCR product contained  complementary  ends  (in- 
cluding the KDEL sequence) that hybridize, and thus it allowed 
amplification of a single DNA fragment using the  other  primers ( A  
and D) used to amplify the fragments. The four oligonucleotide 
primers used were as follows: oligonucleotide A = TACTCCGTAG 
CTCCAGCTTC (identical to bases 41-60 of the mouse metallothi- 
onein-I sense strand regulatory  sequence  (37), i.e. this sequence 
hybridizes to the nonsense strand); oligonucleotide B = GGGTC 
TTCCTA AAG CTC GTC CTT CAT CCT GTA GTT CTT G 
(sequence that is  complementary to  the bases 478-504  of the  sense 
strand  at  the 3' end of the hIGF-IA cDNA, and  containing sequences 
complementary  to  the  KDEL encoding  sequence inserted immediately 
before the stop codon); oligonucleotide C = AC TAC AGG ATG 
AAG(K) GAC(D) GAG(E)  CTT(L)  TAG(stop) GAAGACC CTCCTG 
(sequence  identical to  the 3' end of the hIGF-IA cDNA sense  strand 
sequence, bases 483-509, and the inserted KDEL sequence); and 
oligonucleotide D = ATTAGGAGTT GGAGACCAGC CT (sequence 
complementary to the 3' end of the human growth hormone gene 
sense  strand, bases 2412-2433; Ref. 38).  After  purification of the  first 
PCR products, the two fragments were combined, denatured and 
annealed,  and  then subjected to  PCR with primers A and D to amplify 
a 956-bp fragment with the  KDEL sequence inserted.  This  fragment 
was cut a t  internal BglII and SphI sites, and then subcloned into 
pMIG that was digested at  the same sites. The resulting KDEL 
containing IGF-IA fusion gene was digested  with KpnI  and EcoRI, 
and was subcloned into  pNEONUT at  the same  restriction  sites  (7). 
Panel B, graphic of the  pNEO/IA/KDEL, showing that  the  KDEL 
sequence  is inserted immediately before the  stop codon, as indicated 
in enlarged box. mMT-I, mouse metallothionein-I promoter; rSS,  rat 
somatostatin signal sequence; 3'hGH, 3' end of hGH gene containing 
polyadenylation  signal sequence; Ne0 R, neomycin  resistance gene. 
tion, cell lysate-immunoreactive IGF-I was  320 and 700 pg/ 
lo6 cells and no immunoreactive IGF-I was detectable in 
conditioned media. Northern analysis revealed a single 0.8- 
0.9-kilobase hIGF-IA transcript,  the size expected for  mRNA 
transcribed from this fusion gene (Ref. 7; data not shown). 
The intracellular accumulation of hIGF-I in pNEO/IA/ 
KDEL-transfected cells was further confirmed by labeling 
cellular proteins with [3sS]cysteine and immunoprecipitation 
of hIGF-I using an IGF-I antibody. A radiolabeled 12-14-kDa 
protein,  the predicted size of the  the hIGF-IA precursor, was 
found in pNEO/IA/KDEL-transfected cells and appeared 
nearly identical in size to  the predominant protein found in 
the cell lysates of p5'II/IA-transfected FRTL-5 cells  (Fig. 2). 
A 7-8-kDa radiolabeled protein, representing mature hIGF-I, 
was found in the conditioned media of p5'II/IA-transfected 
cells, but not in that of pNEO/IA/KDEL-transfected cells. 
The addition of the KDEL coding sequence to  the IGF-IA 
fusion  gene, therefore, results in intracellular retention of the 
hIGF-IA transgene product. 
The IGF-IA Precursor and IGF-IAIKDEL Mutant Are Bi- 
ologically Active-To determine if the transgene IGF-IA/ 
KDEL mutant precursor had biological activity comparable 
with that of the precursor without this sequence, the IGF-IA 
precursors from pNEOMIG and  pNEO/IA/KDEL-trans- 
fected FRTL-5 cells  were partially purified using an immu- 
noaffinity method, and  their capacity to stimulate thymidine 
incorporation was assessed in wild type FRTL-5 cells. As 
shown in Table I, the cell lysate IGF-IA precursor prepara- 
tions from both pNEOMIG- and pNEO/IA/KDEL-trans- 
fected FRTL-5 cells exhibited the capacity to stimulate thy- 
midine incorporation when incubated with wild type FRTL- 
5 cells. The pNEO/IA/KDEL cell lysate preparation had a 
greater immunoreactive IGF-I content  than  the pNEOMIG 
preparation  and exhibited greater bioactivity. To exclude the 
possibility that substances other  than IGF-I co-purified from 
FRTL-5 cell lysates (or contaminating substances derived 
from the purification process) might stimulate thymidine 
incorporation, cell lysates from FRTL-5 cells expressing a 
control plasmid (p5'II/NEO that encodes only the neomycin 
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FIG. 2. Characterization of [36S]cysteine-labeled IGF-I 
from either conditioned media or cell lysates of pNEO/IA/ 
KDEL-, p5'11/1A-, or p5'II/NEO-transfected FRTL-5 cells. 
Conditioned  media or cell lysates were incubated with  a polyclonal 
hIGF-I antiserum, and the immunocomplexes were harvested by 
further incubation with protein A-Sepharose, as described under 
"Materials and Methods." These immunocomplexes were analyzed 
by denaturing  15%  SDS-PAGE. The arrows indicate  the location of 
the bands representing the IGF-IA transgene precursors (-14-15 
kDa) and mature (-7-8 kDa) peptides, respectively. Aliquots of 
conditioned media and/or cell lysates from pNEO/IA/KDEL- and 
p5'II/IA-transfected  FRTL-5 cells also were incubated with 100 ng 
of unlabeled recombinant  hIGF-I  prior  to immunoreaction (the lanes 
designated +IGF-I). The absence of a radiolabeled band in these 
lanes indicates that  the  antibody is reacting with authentic IGF-I. 
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TABLE I 
Biological activity of cell lysate  preparations 
Cell lysate  preparations Immunoreactive  Thym dine IGF-I” incorporation* 
~ 1 3 0  P L  dpmlwell 
Coon’s F-12 with 0.1% BSA ND‘ 
p5’  II/NEO 
185 +- 41 
ND 
pNEOMIG 0.25 
177 f 12 
pNEO/IA/KDEL 
1,033 f 69 
3.90 
rhIGF-Id 
3,186 +- 267 
10.00 1,684 +- 253 
” Immunoreactive IGF-I concentrations  are derived from the assay 
of each cell lysate  preparation a t  multiple concentrations  in duplicate. 
* 30 ~l of each preparation was added to 1 ml of medium (Coon’s 
F-12 with 0.1% BSA). The  data represents the mean f S.E. ( n  = 3). 
‘ ND, not detectable. 
Recombinant  hIGF-I. 
resistance gene) were subjected to  the  same  purification  pro- 
cedures. This preparation exhibited neither detectable im- 
munoreactive  IGF-I  nor  the capacity to  stimulate  thymidine 
incorporation  in wild type cells. Compared with recombinant 
hIGF-I,  both  IGF-I  precursor  preparations  exhibited  greater 
bioactivity than would be predicted  based  upon  their  immu- 
noassayable IGF-I, suggesting the possibility that  the  IGF-IA 
precursors  are more potent mitogens than is mature  IGF-I. 
FRTL-5 Cells Expressing the IGF-IAIKDEL Mutant Do 
Not Exhibit the DNA Synthetic Activity of IGF-I-secreting 
Transfected FRTL-5 Cells-To determine  whether  the  intra- 
cellular IGF-IA  expression created  in  pNEO/IA/KDEL- 
transfected  FRTL-5 cells results  in  IGF-I  autocrine  actions, 
we compared TSH-stimulated  DNA  synthesis  in  p5’II/NEO 
(control-transfected cells), pNEOMIG,  and  pNEO/IA/ 
KDEL-transfected  FRTL-5 cells (Fig. 3, top panel). As pre- 
viously demonstrated  in  IGF-I-secreting  transfected  FRTL-5 
cells (pNEOMIG  and p5’II/IA; Ref. 7), TSH  stimulated  thy- 
midine incorporation with a peak response occurring a t  a 
concentration of 1 nM (see pNEOMIG in Fig. 3, top panel). 
In  contrast, cells expressing  the  IGF-IA/KDEL  mutant ex- 
hibited only  a minimal  increase  in  thymidine  incorporation 
in response to  TSH.  This  TSH response  was comparable  with 
that of control-transfected  (p5’II/NEO)  and wild type  (not 
shown)  FRTL-5 cells. Furthermore,  pNEO/IA/KDEL-trans- 
fected cells responded to the addition of TSH with and 
without exogenous IGF-I in a fashion similar to control- 
transfected  and wild type  FRTL-5 cell (Fig. 3, bottom panel). 
The response of the pNEO/IA/KDEL cell lines to IGF-I 
alone, however, was blunted, consistently being about  one- 
third of that observed in non-IGF-expressing cells. In the 
experiment shown in Fig. 3 (bottom panel),  the  IGF-I-secret- 
ing line, pNEOMIG, exhibited a modest increase in DNA 
synthesis  in response to exogenous IGF-I  and a marked  in- 
crease to response to TSH, which is not appreciably aug- 
mented by exogenous IGF-I. Therefore, while the IGF-IA/ 
KDEL  mutant  has  the  capacity  to produce substances  with 
substantial mitogenic activity (see above), its expression in 
transfected FRTL-5 cells does not replicate the autocrine 
actions of IGF-I observed in  IGF-I-secreting  transfected cell 
lines. 
Because the  IGF-I-secreting  FRTL-5 cell lines  pNEOMIG 
and p5’II/IA also express the IGF-IA precursor intracellu- 
larly, we used a monoclonal mouse-derived antibody raised 
against  hIGF-I  (Sm 1.2) to  neutralize media IGF-I as a means 
of determining  whether  the  IGF-I  secreted by these cells was 
responsible  for the increased TSH-stimulated  DNA  synthesis. 
Increasing  concentrations of Sm 1.2 or a control  preparation 
of mIgG were incubated with pNEOMIG (Fig. 4, top panel) 
and p5’II/IA (Fig. 4, bottom panel)  transfected  FRTL-5 cells, 
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FIG. 3. Comparison  of the  effects of TSH and IGF-I on DNA 
synthesis in pNEO/IA/KDEL-, pNEOMIG-, and p5’II/NEO- 
transfected  FRTL-5  cells. Top panel, thymidine  incorporation in 
response to increasing TSH concentrations. Bottom  panel, thymidine 
incorporation stimulated by TSH (1 nM), IGF-I  (10  ng/ml), or both. 
Results  are the means of triplicate wells f S.E.  Note that  the scale 
of the y axis in both  panels is not continuous. 
and  TSH-stimulated  thymidine  incorporation was measured. 
In  both cell lines, Sm 1.2 decreased TSH-stimulated  thymi- 
dine  incorporation in  a dose-dependent  fashion,  with a 90% 
decrease  occurring a t  20 pg/ml and a near-complete  abolition 
occurring a t  100 pg/ml. Similar  concentrations of mIgG had 
only  a minimal effects on  TSH-stimulated  thymidine  incor- 
poration. 
IGF-I-secreting  FRTL-5 Cells Exhibit Increased IGF-bind- 
ing Protein-5 (IGFBP-5) Synthesis, an  Activity That  Is  Not 
Replicated in  IGF-IAIKDEL  Mutant Expressing FRTL-5 
Cells-Because IGF-I is known to  stimulate  the  synthesis of 
some IGFBPs (26, 27), we collected serum-free,  conditioned 
media  from IGF-I-expressing  and  control-transfected  FRTL- 
5 cells and utilized Western ligand  blots to  determine if they 
contained  IGFBPs. As shown in Fig. 5, a  single band  migrating 
at  an  apparent size of 30 kDa  was seen in concentrated (125- 
fold) conditioned media from  each cell line. This  protein was 
identified as  IGFBP-5 by demonstrating  that  the  IGF-binding 
bands  on  the  same ligand blot were immunostained with a 
specific IGFBP-5 antibody (the generous gift of Dr. D.R. 
Clemmons, Department of Medicine, University of North 
Carolina; Ref. 28) and by the identification of a specific 
IGFBP-5 transcript of the expected size (23) in total RNA 
extracted from FRTL-5 cells  (see  below). The  abundance of 
IGFBP-5 was low in  conditioned medium  from control  p5’II/ 
NEO-transfected FRTL-5 cells, as it was in medium from 
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FIG. 4. The inhibitory effect of Sm 1.2, a monoclonal anti- 
body to hIGF-I, on TSH-stimulated DNA synthesis  in IGF-I- 
secreting FRTL-5 cells. Quiescent pNEOMIG (toppanel) or p5'II/ 
IA (bottompanel) transfected FRTL-5 cells were incubated  in Coon's 
modified Ham's F-12 containing 0.1% BSA and  TSH (1 nM) plus Sm 
1.2 (solid  lines) or mouse  IgG (control; broken  lines) at  the concentra- 
tions indicated on the x axis, and [methyl-'Hlthymidine incorporation 
was measured. The results are expressed as means f S.E. of triplicate 
wells. Note that  the scale of the x axis  in  both  panels  is not continuous. 
In addition, error burs that  are  not shown are too  small to be depicted 
with  the markers used. 







FIG. 5. Autoradiogram of a ligand  blot showing IGFBP-5 
in the media conditioned by  control-transfected (p5'II/NEO, 
lane I ) ,  IGF-I-expressing (p5'II/IA and pNEOMIG, lanes 2 
and 4, respectively), and pNEO/IA/KDEL-transfected (pNEO/ 
IA/KDEL, lane 3) FRTL-5 cells. Lane 5 represents 2 p1 of normal 
rat serum. Lanes 1-4 represent the equivalent of 1 ml of original 
conditioned media that was concentrated to 8 pl. The ligand blot was 
exposed to x-ray film for 9 h. The migration of molecular weight 
markers is shown on the right. 
wild type FRTL-5 cells (not shown), but was  more than 30- 
fold  higher  in  media conditioned by p5'II/IA- and pNEOMIG- 
transfected FRTL-5 cells. IGFBP-5 abundance in medium 
conditioned from pNEO/IA/KDEL-transfected cells, how- 
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FIG. 6. The influence of IGF-I and Sm 1.2 on IGFBP-5 
mRNA abundance in  wild type and IGF-I-expressing FRTL- 
5  cells. Northern analysis of IGFBP-5 transcripts was performed 
with total RNA (20 pgllane) using a "P-labeled rat  IGFBP-5 cDNA 
probe. Total RNA was prepared from quiescent wild type, p5'11/1A-, 
p5'II/NEO-,  pNEOMIG-, and pNEO/IA/KDEL-transfected FRTL- 
5 cells that were cultured for 24 h  in Coon's modified Ham's F-12 
containing 0.1% BSA with or without  IGF-I (100 ng/ml) and/or Sm 
1.2 (pg/ml), as indicated. 
ever,  was comparable with that in control-transfected FRTL- 
5 cells. These findings indicate that IGF-I stimulates IGFBP- 
5 synthesis and  that secreted IGF-I is primarily responsible 
for this IGF-I action, as it is  for IGF-I stimulation of DNA 
synthesis. 
Northern analysis of total RNA prepared from  wild type 
and control, p5'II/NEO-transfected FRTL-5 cells demon- 
strated a low abundance 6.0-kilobase transcript that was 
increased about 10-fold  when the cells  were incubated with 
100 ng/ml IGF-I (Fig. 6), findings that confirm IGF-1's ca- 
pacity to stimulate IGFBP-5 synthesis in FRTL-5 cells.  On 
the other  hand, IGF-I-secreting FRTL-5 cells transfected with 
pNEOMIG and p5'II/IA exhibited an abundance of IGFBP- 
5  transcripts comparable with that observed in IGF-I-stimu- 
lated wild type and control-transfected FRTL-5 cells. Fur- 
thermore, incubation of these cells with Sm 1.2 (50 pg/ml) 
reduced IGFBP-5  transcript abundance to  that found in wild 
type and control-transfected FRTL-5 cells not exposed to 
IGF-I. These findings indicate that secreted IGF-I is respon- 
sible for the stimulation of IGFBP-5 expression. Consistent 
with this interpretation is the finding that IGF-IA/KDEL 
expressing cells only exhibit appreciable IGFBP-5 mRNA 
expression when incubated with exogenous IGF-I. Their re- 
sponse to exogenous IGF-I, however, was only about one- 
third  that of wild type or control-transfected cells. In addition, 
the finding that incubation of IGF-IA/KDEL-expressing cells 
with Sm 1.2 abolishes the low abundance IGFBP-5 transcript 
observed under basal conditions suggests that small amounts 
of IGF-IA/KDEL or  mature IGF-I may  be secreted. 
The Influence of IGF-I  and IGF-IAIKDEL Mutant Expres- 
sion on Cell Surface IGF Type I Receptors-Affinity cross- 
linking experiments were performed with wild type and 
pNEO/IA/KDEL- and control (p5'II/NEO)-transfected 
FRTL-5 cells to characterize the cell surface receptors that 
interact with IGF-I (Fig. 7). Under reducing conditions, ra- 
diolabeled IGF-I was cross-linked to a 130-140-kDa protein 
that was nearly obliterated by competition with 200 ng/ml 
unlabeled IGF-I and reduced  in intensity by a 500-fold higher 
concentration (100 pg/ml) of insulin. These findings are  char- 
acteristic of the type I  IGF receptor (29). The radiolabeled 
cross-linked bands migrating at  the top of the gel could 
represent non-reduced type I receptor or the type I1 IGF/ 
mannose-6-phosphate receptor. Because the apparent sizes of 
these bands are >270 kDa and  their intensity is  reduced  by 
competition with insulin, they also likely represent type I 
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FIG. 7. Affinity cross-linking of I2'I-IGF-I to cell surface 
receptors. Wild type,  p5'II/NEO-transfected,  and  pNEO/IA/ 
KDEL-transfected FRLT-5 cells were incubated with '*'II-IGF-I in 
presence or absence of IGF-I (200 ng/ml) or insulin (100 pg/ml), as 
indicated,  and  cross-linked  with  disuccinimidyl  suberate, as described. 
Solubilized samples were  reduced, analyzed by 7.5% SDS-PAGE,  and 
autoradiographed. Molecular  weight markers  are  shown  in  the right 
lane. The  band  migrating a t  about  130  kDa  is  characteristic of the (Y 
subunit of type I IGF receptor. This  interpretation  is  confirmed by 
the  dramatic  reduction of the  intensity of this  band  by 200 ng/ml 
IGF-I and  its  diminution by a 500-fold higher  concentration of insulin 
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FIG. 8. Scatchard plot of I2'I-IGF-I binding to wild type 
(closed circles) and to pNEO/IA/KDEL (crosses), pNEOMIG 
(open squares), and p5'II/IA (closed squares) transfected 
FRTL-5 cells. All FRTL-5 cells were incubated  with "'I-IGF-I in 
Coon's F-12, 0.1% BSA for 24 h, as described. Cell number was 
similar,  as judged by protein  content,  in  each cell line  (range 191.4 f 
4 pg/well to 218.3 ? 20.3 pg/well; mean k S.D.). Each data point 
represents  the  mean of duplicate  experiments. 
receptors (the type I1 receptor migrates a t  -250 kDa under 
reducing conditions, -220 kDa under non-reducing condi- 
tions,  and does not bind  insulin; Ref. 29). 
To determine if expression of IGF-I  or  the  IGF-I/KDEL 
mutant altered receptor affinity and/or number, '251-IGF-I 
binding to each FRTL-5 cell line was determined in the 
presence of increasing concentrations of unlabeled IGF-I. 
Specific binding was greatest in wild type  FRTL-5 cells (10.08 
and 10.55% in two experiments), modestly lower in pNEO/ 
IA/KDEL-transfected cells (8.36 and 8.49%), and much lower 
in IGF-I-secreting cells (5.81 and 6.21% in  pNEOMIG  and 
p5'11/1A cells, respectively). Scatchard plots of IGF-I  binding 
in each cell line were linear (Fig. 8), and, therefore, IGF-I 
appears  to  interact with  a single class of receptors,  a  finding 
that is in accord with the affinity  cross-linking  studies. The 
receptor concentrations (calculated from the x intercept of 
the  Scatchard plot) were lower in IGF-I-secreting cells (29.5 
and 28.3 PM in  pNEOMIG-  and p5'II/IA-transfected FRTL- 
5, respectively) compared to wild type  FRTL-5 cells (41.4 p ~ ) ,  
suggesting that IGF-I secretion results in type I receptor 
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down-regulation. A  minimal  reduction of type  I  receptor con- 
centration was observed in pNEO/IA/KDEL-transfected cells 
(37.4 uersus 41.4 PM in wild type cells). This reduction also 
may reflect  receptor  down-regulation by the secretion of small 
amounts of IGF-IA/KDEL or  mature IGF-I. The affinities of 
IGF-I binding, however, were similar in each cell line ( K d  = 
0.35,  0.38, 0.43, and 0.39 nM for wild type,  pNEO/IA/KDEL, 
pNEOMIG, and p5'II/IA FRTL-5 cells, respectively). 
DISCUSSION 
The results of this  study provide strong evidence that  the 
dominant mechanism of IGF-I autocrine actions  are effected 
by secreted IGF-I and its subsequent interaction with cell 
surface receptors. Specifically, we have shown that IGF-I 
expression in FRTL-5 cells results in an autocrine  phenotype 
when expression results  in IGF-I secretion, while this phe- 
notype does not occur when IGF-I expression is predomi- 
nately  intracellular. Furthermore,  in  FRTL-5 cell lines  exhib- 
iting IGF-I autocrine actions, exposure to  an IGF-I  antibody 
blocks IGF-I-stimulated activity, again indicating that the 
activities observed are exerted by the media-secreted IGF-I. 
Using in vitro radiolabeling, we found that  mature IGF-I is 
the major form of secreted  IGF-I, while the IGF-IA or IGF- 
IA/KDEL  precursor  forms  predominate  intracellularly. The 
molecular form of the IGF-I expressed, however, does not 
account for the differing phenotypes in these transfected 
FRTL-5 cell lines, because we have shown that each of the 
IGF-I  precursors  expressed has biological potency that is a t  
least comparable  with that of mature recombinant  hIGF-I. 
In this study we assessed IGF-I actions using two inde- 
pendent measures, thymidine incorporation and IGFBP-5 
gene expression. IGF-1's stimulation of these activities  prob- 
ably involves differing mechanisms because IGF-1's major 
effects on DNA synthesis in FRTL-5 cells are exerted in 
concert with TSH, while its capacity to increase IGFBP-5 
expression does not require  additional exogenous regulatory 
factors.  Nonetheless, our  data show that  both of these IGF-I 
actions  is imilarly dependent upon IGF-I secretion. Although 
each  action may be exerted through differing ultimate  path- 
ways,  IGF-1's signaling  mechanism appears  to be shared  and 
to result from the  interaction of secreted  IGF-I and  the cell 
surface type I IGF receptor. The affinity  cross-linking  studies 
confirm the expression of the type  I receptor on the  FRTL-5 
cell surface. They also suggest that  the  type I receptor is the 
major, if not  the only, FRTL-5 cell surface  protein capable of 
binding IGF-I. This  interpretation is supported by the  Scat- 
chard analyses of FRTL-5 cell IGF-I  binding data, because 
the linear  plots derived from these analyses  indicate  a single 
class of receptors. The  Scatchard analyses  also  indicate that 
receptor concentration is reduced in IGF-I-secreting FRTL-5 
cells, a finding that can be taken as further evidence of 
secreted IGF-1's interaction with the cell surface  type  I recep- 
tor. 
As anticipated,  expression of the IGF-IA/KDEL mutant in 
FRTL-5 cells resulted  in the intracellular  accumulation of the 
IGF-IA/KDEL  precursor. The  KDEL amino acid sequence is 
recognized by specific binding sites in the endoplasmic retic- 
ulum, and, thus, proteins containing this and similar se- 
quences are  retained intracellularly as  they  are cycled through 
the endoplasmic reticulum and Golgi apparatus  (12,13). Such 
binding of KDEL-containing proteins, however, does not ex- 
clude protein processing or secretion. We were unable to 
detect  secreted  IGF-I in  the IGF-IA/KDEL-expressing 
FRTL-5 cells. Two  findings  in  IGF-IA/KDEL-expressing cell 
lines, however, suggest that small amounts of IGF-I were 
secreted. 1) The low abundance IGFBP-5 mRNA observed in 
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IGF-IA/KDEL-expressing cells under  basal  conditions could 
not be visualized when cells were exposed to  the  antibody  to 
IGF-I. 2) Iz5I-IGF-I specific binding  and  the calculated  recep- 
tor  concentration  is modestly  reduced  in these cells. Of poten- 
tial  importance is the  finding  that  IGF-IA/KDEL-expressing 
cells exhibited a diminished response to exogenous IGF-I, 
being about one-third that of wild type and control-trans- 
fected cells for both  thymidine  incorporation  and  IGFBP-5 
expression.  The possible reduction  in  receptor  number  exhib- 
ited by the IGF-IA/KDEL-expressing cells does not seem 
responsible  for this  blunted  IGF-I response,  because the  IGF- 
I-secreting FRTL-5 cell lines have a greater reduction in 
receptor  number,  yet  they  respond  exuberantly  to  the  IGF-I 
that  they secrete.  We  speculate, therefore,  that  the  intracel- 
lular  accumulation of IGF-IA/KDEL  partially blocks  signal 
transduction  mechanisms triggered in response to  the  inter- 
action of IGF-I  and  its receptor. Such a desensitization  to  the 
actions of IGF-I  has been reported  in mouse L cells overex- 
pressing  an  IGF-I  transgene  (30)  and  in  HTC  rat  hepatoma 
cells preincubated  with exogenous IGF-I (31). In  these  studies, 
neither  changes in receptor  affinity  nor  in  receptor  number 
were  sufficient to  account for the decrease in responsiveness 
While  our findings strongly  argue  that  secreted  IGF-I  is a 
major effector of IGF-1’s autocrine  actions,  they  do  not ex- 
clude actions of intracellular IGF-I or its precursors. The 
IGF-I-secreting  FRTL-5 cell lines  express  the  IGF-IA  precur- 
sor  and  mature  IGF-I  intracellularly.  Either of these  proteins 
could exert intracellular actions that make the effects of 
secreted  IGF-I possible. In  addition,  our  findings suggesting 
a desensitization of IGF-IA/KDEL-expressing cells to exog- 
enous  IGF-I also  argue  for intracellular  IGF-I  actions. 
Evidence that growth factors can act intracellularly has 
been reported. For example,  expression of interleukin-3  pos- 
sessing a carboxyl-terminal  KDEL signal  been  shown to  make 
32D cells independent of their  requirement for this growth 
factor  (32). Evidence for intracellular  autocrine  actions of the 
v-sis  protein  product,  the  viral homolog of the  platelet-derived 
growth factor B chain, also  have  been reported  (33,34).  Other 
reports, however, provide  evidence that v-sis protein  actions 
require  interaction  with  the  platelet-derived growth factor cell 
surface receptor (35, 36) .  Whether growth factors  can  exert 
their  autocrine  action  intracellularly,  therefore,  remains  con- 
troversial. It seems likely that the mechanisms of growth 
factor autocrine actions will prove to differ with different 
growth factors  and  to be dependent  upon  nature of the  ex- 
pressing cell. 
to IGF-I. 
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